Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association.
Cardiac computed tomography; Cardiac magnetic resonance; Cardiac nuclear imaging; Echocardiography; Hypertrophic cardiomyopathy; Left ventricular hypertrophy; Multimodality imaging
Abstract :
[en] Taking into account the complexity and limitations of clinical assessment in hypertrophic cardiomyopathy (HCM), imaging techniques play an essential role in the evaluation of patients with this disease. Thus, in HCM patients, imaging provides solutions for most clinical needs, from diagnosis to prognosis and risk stratification, from anatomical and functional assessment to ischaemia detection, from metabolic evaluation to monitoring of treatment modalities, from staging and clinical profiles to follow-up, and from family screening and preclinical diagnosis to differential diagnosis. Accordingly, a multimodality imaging (MMI) approach (including echocardiography, cardiac magnetic resonance, cardiac computed tomography, and cardiac nuclear imaging) is encouraged in the assessment of these patients. The choice of which technique to use should be based on a broad perspective and expert knowledge of what each technique has to offer, including its specific advantages and disadvantages. Experts in different imaging techniques should collaborate and the different methods should be seen as complementary, not as competitors. Each test must be selected in an integrated and rational way in order to provide clear answers to specific clinical questions and problems, trying to avoid redundant and duplicated information, taking into account its availability, benefits, risks, and cost.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Cardim, Nuno
Galderisi, Maurizio
Edvardsen, Thor
Plein, Sven
Popescu, Bogdan Alexandru
D'Andrea, Antonello
Bruder, Oliver
Cosyns, Bernard
DAVIN, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Donal, Erwan
Freitas, Antonio
Habib, Gilbert
Kitsiou, Anastasia
Petersen, Steffen E.
Schroeder, Stephen
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie
Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association.
Publication date :
2015
Journal title :
European Heart Journal. Cardiovascular Imaging
ISSN :
2047-2404
eISSN :
2047-2412
Publisher :
Oxford University Press, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author 2015. For permissions please email: journals.permissions@oup.com.
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29:270-6.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al. 2011 ACCF/ AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2011;58:e212-60.
Maron B. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.
Zou Y, Song L, Wang Z,Ma A, Liu T, Gu H et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004;116:14-8.
Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008;19:104-10.
Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54: 201-11.
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years. J Am Coll Cardiol 2012;60:705-15.
Arad M, Maron BJ, Gorham JM, Johnson WH,Saul JP, Perez-Atayde AR et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-72.
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, CalkinsHet al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011;8:1308-39.
Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2008;52:1990-6.
Moon JCC, Reed E, Sheppard MN, Elkington AG,HoS, BurkeMet al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-4.
Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:242-9.
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, GibsonCMet al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-74.
Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561-7.
Elliott P, Anastasakis A, Borger M, BorggrefeMF, Cecchi F, Charron Pet al. 2014ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014;35:2733-79.
Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. The Lancet 2004;363: 1881-91.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-20.
Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B et al. Research priorities in hypertrophic cardiomyopathy: report of a working group of the National Heart, Lung, and Blood Institute. Circulation 2010;122:1130-3.
Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 2012;5:535-46.
Ferrantini C, Belus A, Piroddi N, Scellini B, Tesi C, Poggesi C. Mechanical and energetic consequences of HCM-causing mutations. J Cardiovasc Trans Res 2009;2: 441-51.
Bai F,Weis A, Takeda AK,Chase PB, Kawai M. Enhanced active cross-bridges during diastole: molecular pathogenesis of Tropomyosin's HCM mutations. Biophys J Biophys Soc 2011;100:1014-23.
Ho CYC, López BB, Coelho-Filho ORO, Lakdawala NKN, Cirino ALA, Jarolim PP et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-63.
Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54: 866-75.
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;1:184-91.
Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:261-7.
Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L et al. Dilatedhypokinetic evolution of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46: 1543-50.
Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98: 960-5.
Olivotto I, Girolami F, Nistri S, Rossi A, Rega L, Garbini F et al. The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. J Cardiovasc Trans Res 2009;2:349-67.
Olivotto I, Girolami F, Sciagrà R, Ackerman MJ, Sotgia B, Bos JM et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 2011;58:839-48.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R,Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007; 115:2418-25.
Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B et al. American Society of Echocardiography Clinical Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2011;24:473-98.
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi Cet al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35:2010-20.
Bruder O,Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.
O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S,Wage R et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009;54:220-8.
Maron BJ, Epstein SE. Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. Am J Cardiol 1986;58:1093-6.
McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2.
Klues HG, Schiffers A, Maron BJ. Phenotypic spectrumand patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708.
Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
Rose AG. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy. Histopathology 1984;8:395-406.
Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 1983;2:437-44.
Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1-83.
Chang S-A, Kim H-K, Lee S-C, Kim E-Y, Hahm S-H, Kwon OMet al. Assessment of left ventricular mass in hypertrophic cardiomyopathy by real-time threedimensional echocardiography using single-beat capture image. J Am Soc Echocardiogr 2013;26:436-42.
Kwon DH, Smedira NG, Popović ZB, Lytle BW, Setser RM, Thamilarasan M et al. Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using three-dimensional multimodality imaging. Heart 2009;95:1784-91.
de Gregorio C, Recupero A, Grimaldi P, Coglitore S. Can transthoracic live 3-dimensional echocardiography improve the recognition of midventricular obliteration in hypertrophic obstructive cardiomyopathy? J Am Soc Echocardiogr 2006; 19:1190.e1-e4.
Moon JCC. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004;90:645-9.
Rickers C, WilkeNM, Jerosch-Herold M, Casey SA, Panse P, PanseNet al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855-61.
Maron BJ, Haas TS, Lesser JR. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy. Circulation 2007;115:e627-8.
Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascularmagnetic resonance. J Cardiovasc Magn Reson 2005;7:551-8.
Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011;124:40-7.
Cavalcante JL, Barboza JS, Lever HM. Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2012;54:517-22.
Klues HG, Proschan MA, Dollar AL, Spirito P, Roberts WC, Maron BJ. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. Circulation 1993;88:548-55.
Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Piérard LA et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-44.
Lafitte S, Reant P, Touche C, Pillois X, Dijos M, Arsac F et al. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics. J Am Coll Cardiol 2013;62:842-50.
Maron MSM. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J Cardiovasc Trans Res 2009;2:415-25.
Alkadhi H, Desbiolles L, Stolzmann P, Leschka S, Scheffel H, Plass A et al. Mitral annular shape, size, and motion in normals and in patients with cardiomyopathy: evaluation with computed tomography. Invest Radiol 2009;44:218-25.
Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
Shah JS, Esteban MTT, Thaman R, Sharma R, Mist B, Pantazis A et al. Prevalence of exercise-induced left ventricularoutflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2007;94:1288-94.
Levine RA, Vlahakes GJ, Lefebvre X, Guerrero JL, Cape EG, Yoganathan AP et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 1995;91:1189-95.
Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:461-6.
Cardim N, Campos P, Ferreira D, Carmelo V, Toste J, TrabuloMet al. Are intraventricular gradients a cause of false positive treadmill exercise tests? Rev Port Cardiol 2012;31:485-92.
Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232-9.
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, PoldermansD et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008;9:415-37.
Williams TJ, Manghat NE, Mckay-Ferguson A, Ring NJ, Morgan-Hughes GJ, Roobottom CA. Cardiomyopathy: appearances on ECG-gated 64-detector row computed tomography. Clin Radiol 2008;63:464-74.
Takx RAP, Moscariello A, Schoepf UJ, Barraza JM Jr, Nance JW Jr, BastarrikaGet al. Quantification of left and right ventricular function and myocardial mass: comparison of low-radiation dose 2nd generation dual-source CT and cardiac MRI. Eur J Radiol 2012;81:e598-604.
Grbic S, Ionasec R, Vitanovski D, Voigt I, Wang Y, Georgescu B et al. Complete valvular heart apparatus model from 4D cardiac CT. Med Image Comput Comput Assist Interv 2010;13(Pt 1):218-26.
Beaudoin J, Thai W-E,Wai B, Handschumacher MD, Levine RA, Truong QA. Assessment of mitral valve adaptation with gated cardiac computed tomography: validation with three-dimensional echocardiography and mechanistic insight to functional mitral regurgitation. Circ Cardiovasc Imaging 2013;6:784-9.
Weidemann F, Niemann M, Herrmann S, Kung M, Störk S,Waller C et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28:3020-6.
Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE Consensus Statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr 2011;12:167-205.
Almaas VM, Haugaa KH, Strøm EH, Scott H, Smith H-J, Dahl CP et al. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. Heart 2013;100:631-8.
Todiere G, AquaroGD,Piaggi P, Formisano F, Barison A, MasciPGet al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2012;60:922-9.
Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-EdwardsAet al. Myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol Imaging 2013;6: 587-96.
Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. J Am Coll Cardiol Imaging 2013;6:597-9.
Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy.A population-based study, 1976 through 1990. Circulation 1995;92:2488-95.
Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
Suk T, Edwards C, Hart H, Christiansen JP. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ 2008;17: 370-4.
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484-95.
Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 2014;100:1851-8.
ToACY, Dhillon A, DesaiMY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol Imaging 2011;4:1123-37.
Won S, Davies-Venn C, Liu S, Bluemke DA. Noninvasive imaging of myocardial extracellular matrix for assessment of fibrosis. Curr Opin Cardiol 2013;28:282-9.
Flett AS, HaywardMP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM et al. Equilibrium contrast cardiovascularmagnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010;122:138-44.
Lee W-N, Larrat B, Pernot M, Tanter M. Ultrasound elastic tensor imaging: comparison with MR diffusion tensor imaging in the myocardium. Phys Med Biol 2012; 57:5075-95.
Zhao L, Ma X, Delano MC, Jiang T, Zhang C, Liu Y et al. Assessment of myocardial fibrosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: comparison with MR and coronary angiography. Eur Radiol 2013;23:1034-43.
MacIver DH. A new method for quantification of left ventricular systolic function using a corrected ejection fraction. Eur J Echocardiogr 2011;12:228-34.
Ho CYC, Solomon SDS. A clinician's guide to tissue Doppler imaging. Circulation 2006;113:e396-8.
CardimN, Longo S, Ferreira T, Pereira A, Gouveia A, Reis RP et al. Tissue Doppler imaging assessment of long axis left ventricular function in hypertensive patients with concentric left ventricular hypertrophy: differential diagnosis with hypertrophic cardiomyopathy. Rev Port Cardiol 2002;21:709-40.
Oki T, Mishiro Y, Yamada H, Onose Y, Matsuoka M,Wakatsuki T et al. Detection of left ventricular regional relaxation abnormalities and asynchrony in patients with hypertrophic cardiomyopathy with the use of tissue Doppler imaging. Am Heart J 2000;139:497-502.
McMahon CJ. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109:1756-62.
Bayrak F, Kahveci G, Mutlu B, Sonmez K, Degertekin M. Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy. Eur J Echocardiogr 2008;9:278-83.
D'Andrea A. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes∗ Commentary. Br J Sports Med 2006;40:244-50. discussion 244-50.
Edvardsen T. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against threedimensional tagged magnetic resonance imaging. Circulation 2002;106:50-6.
Sengupta PP, MehtaV, Arora R, Mohan JC, Khandheria BK. Quantification of regional nonuniformity and paradoxical intramural mechanics in hypertrophic cardiomyopathy by high frame rate ultrasound myocardial strain mapping. J Am Soc Echocardiogr 2005;18:737-42.
Yang H, Sun JP, Lever HM, Popovic ZB, Drinko JK, Greenberg NL et al. Use of strain imaging in detecting segmental dysfunction in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2003;16:233-9.
Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography. J Am Coll Cardiol 2006;47:789-93.
Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R et al. Global and regional myocardial function quantification by two-dimensional strain. J Am Coll Cardiol 2006;47:1175-81.
Carasso S, Yang H,Woo A, Vannan MA, Jamorski M, Wigle ED et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: novel concepts and implications for clinical status. J Am Soc Echocardiogr 2008;21:675-83.
Nagueh SF. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003;108:395-8.
Thaman R. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005;91:920-5.
Popović ZB, Kwon DH, Mishra M, Buakhamsri A, Greenberg NL, Thamilarasan M et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr 2008;21:1299-305.
Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2012;13:617-23.
Pacileo G, Baldini L, Limongelli G, Di Salvo G, Iacomino M, CapogrossoCet al. Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr 2011;12:841-9.
Ennis DB, Epstein FH, Kellman P, Fananapazir L, McVeigh ER, Arai AE. Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging. Magn Reson Med 2003;50:638-42.
Kim YJ, Choi BW, Hur J, Lee H-J, Seo JS, Kim TH et al. Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI. J Magn Reson Imaging 2008;27:1054-60.
Shirani J, Dilsizian V. Nuclear cardiac imaging in hypertrophic cardiomyopathy. J Nucl Cardiol 2011;18:123-34.
Spindler M, SaupeKW, ChristeME, SweeneyHL, Seidman CE, Seidman JG et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:1775-83.
Ohsato K, Shimizu M, Sugihara N, Konishi K, Takeda R. Histopathological factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 1992;56:325-33.
Rakowski H, Carasso S. Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the Holy Grail. Circulation 2007;116:2662-5.
Maron BJ, Ferrans VJ, HenryWL,Clark CE, Redwood DR, RobertsWCet al. Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH): light and electron microscopic findings. Circulation 1974;50:436-46.
Nishimura RA, Appleton CP, Redfield MM, Ilstrup DM, Holmes DR, Tajik AJ. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 1996;28:1226-33.
Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254-61.
Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007;116:2702-8.
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2008;10:165-93.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517-24.
Yang H,Woo A, Monakier D, Jamorski M, Fedwick K, Wigle ED et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr 2005;18:1074-82.
Paraskevaidis IA, Panou F, Papadopoulos C, Farmakis D, Parissis J, Ikonomidis I et al. Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and two-dimensional strain study. Heart 2009;95:483-9.
Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;34:1123-8.
Anwar AM, Soliman O II, Nemes A, Geleijnse ML, Cate ten FJ. An integrated approach to determine left atrial volume, mass and function in hypertrophic cardiomyopathy by two-dimensional echocardiography. Int J Cardiovasc Imaging 2007;24: 45-52.
Roşca M, Popescu BA, Beladan CC, Calin A, Muraru D, Popa ECet al. Left atrial dysfunction as a correlate of heart failure symptoms in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2010;23:1090-8.
Severino S, Caso P, Galderisi M, De Simone L, Petrocelli A, de DivitiisOet al. Use of pulsed Doppler tissue imaging to assess regional left ventricular diastolic dysfunction in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1394-8.
Matsumura Y, Elliott PM, Virdee MS, Sorajja P, Doi Y, McKenna WJ. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 2002;87:247-51.
Carasso S, Yang H,Woo A, Jamorski M, Wigle ED, Rakowski H. Diastolic myocardial mechanics in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2010;23: 164-71.
Boonyasirinant T, Rajiah P, Setser RM, Lieber ML, Lever HM, Desai MY et al. Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis. J Am Coll Cardiol 2009;54:255-62.
Austin BA, Popovic ZB, Kwon DH, Thamilarasan M, Boonyasirinant T, Flamm SD et al. Aortic stiffness independently predicts exercise capacity in hypertrophic cardiomyopathy: a multimodality imaging study. Heart 2010;96:1303-10.
Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and longterm effects. Circulation 1985;72:853-64.
Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow RO,Watson RM et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
Basso C. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.
Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 1998;31:1089-96.
McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002;87:169-76.
Cortigiani L, Rigo F, Gherardi S, Galderisi M, Sicari R, Picano E. Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy. Am J Cardiol 2008;102:1718-23.
Lazzeroni E, Picano E, Dodi C, Morozzi L, Chiriatti GP, Lu C et al. Dipyridamole echocardiography for diagnosis of coexistent coronary artery disease in hypertrophic cardiomyopathy. Echo-Persantine International Cooperative (EPIC) Study Group - subproject hypertrophic cardiomyopathy. Am J Cardiol 1995;75: 810-3.
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, PoldermansD et al. Stress Echocardiography Expert Consensus Statement - executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J 2008;30:278-89.
Peteiro J, Bouzas-Mosquera A, Fernandez X, Monserrat L, Pazos P, Estevez-Loureiro R et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012;25:182-9.
Knaapen P, van Dockum WG, Götte MJ, Broeze KA, Kuijer JP, Zwanenburg JJ et al. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. J Nucl Cardiol 2006;13:660-7.
O'Gara PT, Bonow RO, Maron BJ, Damske BA, Van Lingen A, Bacharach SL et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987; 76:1214-23.
Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Tucker E, Panza JA et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992;85:1039-45.
Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV et al. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on leftventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging. Int J Cardiovasc Imaging 2012;28:1375-84.
Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
Olivotto I, Cecchi F, Camici PG. Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. Ital Heart J 2004;5:572-80.
Choudhury L, Rosen SD, Lefroy DC, Nihoyannopoulos P, Oakley CM, Camici PG. Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy. Eur Heart J 1996;17:1703-9.
Choudhury LL, Elliott PP, Rimoldi OO, Ryan MM, Lammertsma AAA, Boyd HH et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.
Bourassa MG, Butnaru A, Lespérance J, Tardif J-C. Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol 2003;41:351-9.
Schwarz ER, Klues HG, Dahl vom J, Klein I, KrebsW, Hanrath P. Functional characteristics of myocardial bridging. A combined angiographic and intracoronary Doppler flow study. Eur Heart J 1997;18:434-42.
Schwarz ER, Klues HG, Dahl vom J, Klein I, KrebsW, Hanrath P. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. J Am Coll Cardiol 1996;27:1637-45.
Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. Eur Heart J 2009;30: 1627-34.
Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri F, de Feyter P et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a writing group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J 2008;29:531-56.
Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O'Gara P et al. ACCF/SCCT/ ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation 2010;122:e525-55.
Menke J, Unterberg-Buchwald C, Staab W, Sohns JM, Hosseini ASA, Schwarz A. Head-to-head comparison of prospectively triggered vs retrospectively gated coronary computed tomography angiography: meta-analysis of diagnostic accuracy, image quality, and radiation dose. Am Heart J 2013;165:154-63.e3.
Bamberg F, Sommer WH, Hoffmann V, Achenbach S, Nikolaou K, Conen D et al. Meta-analysis and systematic review of the long-term predictive value of assessment of coronary atherosclerosis by contrast-enhanced coronary computed tomography angiography. J Am Coll Cardiol 2011;57:2426-36.
Nakanishi R, Park HB, Arsanjani R, Berman DS, Min JK. Coronary CT angiography can be used as a substitute for coronary angiography in patients with significant LV dysfunction. Prog Cardiovasc Dis 2013;55:498-503.
Leschka S, Koepfli P, Husmann L, Plass A, Vachenauer R, Gaemperli O et al. Myocardial bridging: depiction rate and morphology at CT coronary angiography - comparison with conventional coronary angiography. Radiology 2008;246:754-62.
Ma E-S, Ma G-L, Yu H-W,WuW, Li K. Assessment of myocardial bridge and mural coronary artery using ECG-gated 256-slice CT angiography: a retrospective study. TheScientificWorld J 2013;2013:947876, 6 pages.
Sundaram B, Patel S, Bogot N, Kazerooni EA. Anatomy and terminology for the interpretation and reporting of cardiac MDCT: part 1, structured report, coronary calcium screening, and coronary artery anatomy. AJR Am J Roentgenol 2009;192: 574-83.
Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-42.
Crilley JG, Boehm EA, Blair E, Rajagopalan B, BlamireAM, Styles P et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-82.
Zhao C, Shuke N, Okizaki A, YamamotoW, Sato J, Ishikawa Y et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cardiomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med 2003;17:541-8.
Amano Y, Kumita S, Takayama M, Kumazaki T. Comparison of contrast-enhanced MRI with iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR Am J Roentgenol 2005;185:312-8.
Shiba N, KagayaY, Ishide N, Otani H, Takeyama D, YamaneYet al. Heterogeneity of myocardial fluoro-18 2-deoxyglucose uptake in patients with apical hypertrophic cardiomyopathy. Jpn Circ J 1997;61:223-30.
Schäfers MM, Dutka DD, Rhodes CGC, Lammertsma AAA, Hermansen FF, SchoberOOet al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998;82:57-62.
Zhao C, Shuke N, YamamotoW, Okizaki A, Sato J, Ishikawa Y et al. Comparison of cardiac sympathetic nervous function with left ventricular function and perfusion in cardiomyopathies by (123)I-MIBG SPECT and (99 m)Tc-tetrofosmin electrocardiographically gated SPECT. J Nucl Med 2001;42:1017-24.
Matsunari I, Aoki H, NomuraY, Takeda N, ChenWP, Taki J et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging 2010;3:595-603.
Pacileo G, De Cristofaro M, Russo MG, Sarubbi B, Pisacane C, Calabro R. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. Can J Cardiol 2000;16:146-52.
Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to firstline therapy with b-blockade or verapamil. Circ Heart Fail 2013;6:694-702.
Marian AJ. Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Trans Res 2009;2:483-92.
Bonow RO, OstrowHG, Rosing DR, Cannon RO, Lipson LC, Maron BJ et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation 1983;68:1062-73.
Marwick TH, Stewart WJ, Lever HM, LytleBW, Rosenkranz ER, Duffy CI et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;20:1066-72.
MorrowAG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
Sasson Z, Prieur T, Skrobik Y, Fulop JC, Williams WG, Henderson MA et al. Aortic regurgitation: a common complication after surgery for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1989;13:63-7.
Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:668-73.
Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008;94:1295-301.
Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg [Internet] 2004;127:481-9.
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012;14:13.
Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. J Am Coll Cardiol 2010;55:2614-62.
Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000;13:1074-9.
Monakier D, Horlick E, Ross J,Woo A, Rakowski H, Schwartz L et al. Intracoronary myocardial contrast echocardiography in a patient with drug refractory hypertrophic obstructive cardiomyopathy revealing extensive myocardium at risk for infarction with alcohol septal ablation. J Invasive Cardiol 2004;16:482-4.
Lothar F, Seggewissb H,Welgea D, Fassbendera D, Schmidta HK, Gleichmanna U et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004;5:347-55.
Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208-14.
Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-5.
Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49:350-7.
van Dockum WG. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005;111:2503-8.
van Dockum WG, Cate ten FJ, Berg ten JM, Beek AM, Twisk JWR, Vos J et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.
Yuan J, Qiao S, Zhang Y, You S, Duan F, Hu F et al. Follow-up by cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy who underwent percutaneous ventricular septal ablation. Am J Cardiol 2010;106:1487-91.
van Dockum WG, Kuijer JPA, Gotte MJW, Cate ten FJ, Berg ten JM, Beek AM et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J 2006;27:2833-9.
Nieman K, Shapiro MD, Ferencik M, Nomura CH, Abbara S, Hoffmann U et al. Reperfused myocardial infarction: contrast-enhanced 64-section CT in comparison to MR imaging 1. Radiology 2008;247:49-56.
Tsai I-C, Lee W-L, Tsao C-R, Chang Y, Chen M-C, Lee T et al. Comprehensive evaluation of ischemic heart disease using MDCT. AJR Am J Roentgenol 2008;191: 64-72.
Members WC, Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC et al. ACCF/ ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document oncoronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010;55:2663-99.
Orakzai SH, Orakzai RH, Nasir K, Budoff MJ. Assessment of cardiac function using multidetector row computed tomography. J Comput Assist Tomogr 2006;30: 555-63.
Gerber BL. Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance. Circulation 2006;113:823-33.
Aqel RA, Hage FG, Zohgbi GJ, Tabereaux PB, Lawson D, Heo J et al. Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol 2008;101:1328-33.
Thomson H, Fong W, Stafford W, Frenneaux M. Reversible ischaemia in hypertrophic cardiomyopathy. Heart 1995;74:220-3.
Posma JL, Posma JL, Blanksma PK, Blanksma PK, van derWall EE, van derWall EE et al. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart 1996;76:358-62.
Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44: 2125-32.
CardimN, Perrot A, Ferreira T et al. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol 2002;90:128-32.
Nagueh SF, Bachinski LL, Meyer D, Hill R, ZoghbiWA, TamJWet al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:128-30.
Yiu KH, Atsma DE, Delgado V, Ng ACT, Witkowski TG, Ewe SH et al. Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. PLoS ONE 2012;7:e36115.
Forsey J, Benson L, Rozenblyum E, Friedberg MK, Mertens L. Early changes in apical rotation in genotype positive children with hypertrophic cardiomyopathy mutations without hypertrophic changes on two-dimensional imaging. J Am Soc Echocardiogr 2014;27:215-21.
Germans T, Wilde AAM, Dijkmans PA, ChaiW, Kamp O, Pinto YM et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006;48:2518-23.
Brouwer WPW, Germans TT, Head MCM, van der Velden JJ, Heymans MWM, Christiaans II et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging 2012;13:292-7.
Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J 2014;35:2706-13.
Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. J Am Coll Cardiol Img 2012;5:119-22.
Germans T, Rüssel IK, Götte MJ, Spreeuwenberg MD, Doevendans PA, Pinto YM et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:13.
Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010;121: 445-56.
Harris KM. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114: 216-25.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
Elliott PM, Gimeno JR, Tome MT, Shah J,Ward D, Thaman R et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41.
Liu D, Niemann M, Hu K, Herrmann S, Störk S, Knop S et al. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol 2011;108:591-8.
Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8.
Rapezzi CC, Longhi SS, Milandri AA, Lorenzini MM, Gagliardi CC, Gallelli II et al. Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid 2012;19(Suppl 1):16-21.
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Imaging 2013;6:488-97.
Kato TS. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 2004;110:3808-14.
Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy: relation to remodeling. J Am Coll Cardiol 2009;53:284-91.
O'Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis 2010;52:326-35.
Tafanelli L,Avierinos J-F, Thuny F, Pelissier J-F, Jacquier A, Renard S et al. [Mitochondrial cardiomyopathy in an adult: a case history]. Arch Mal Coeur Vaiss 2007;100: 1021-4.
Bates MGD, Bourke JP, Giordano C, d'Amati G, Turnbull DM, TaylorRW. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J 2012;33:3023-33.
Bates MGD, Hollingsworth KG, Newman JH, Jakovljevic DG, Blamire AM, MacGowan GA et al. Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers. Eur Heart J Cardiovasc Imaging 2013;14:650-8.
Habib G, Charron P, Eicher J-C, Giorgi R, Donal E, LapercheTet al. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients. Results from a French registry. Eur J Heart Fail 2011;13:177-85.
Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 2010;31:1098-104.
Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. The Lancet 2013; 381:333-42.
Kawasaki T, Yamano M, Sakai C, Harimoto K, Miki S, Kamitani T et al. Diagnostic performance of ultrasonic tissue characterization for subendocardial ischaemia in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2013;14:790-6.
Pernot M, Couade M, Mateo P, Crozatier B, Fischmeister R, Tanter M. Real-time assessment of myocardial contractility using shear wave imaging. J Am Coll Cardiol 2011;58:65-72.